Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.44 |
| ▸ | SCN4A | P35499 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10437691 | 0.85 | MAPT (0.50) | KDM1AALDH1A1GAAMAPTCYP2C19 | |
| SCHEMBL9967704 | 0.81 | KDM1A (0.56) | KDM1AALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL8134520 | 0.81 | ALDH1A1 (0.73) | KDM1AALDH1A1GAAMAPTCYP2C19 | |
| SCHEMBL325648 | 0.80 | SCN4A (0.60) | KDM1AALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL3794233 | 0.79 | MAPT (0.68) | ALDH1A1GAAMAPTCYP2C19CYP1A2 | |
| SCHEMBL3727775 | 0.79 | KDM1A (0.54) | KDM1AALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL278545 | 0.79 | KDM1A (0.54) | KDM1AALDH1A1GAAMAPTPTGER1 | |
| SCHEMBL13347438 | 0.79 | KDM1A (0.54) | KDM1AALDH1A1GAAMAPTCYP2C19 | |
| SCHEMBL4069141 | 0.79 | KDM1A (0.54) | KDM1AALDH1A1GAAMAPTXDH | |
| SCHEMBL13676822 | 0.79 | KDM1A (0.54) | KDM1AALDH1A1GAAPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003219-A | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-07-12 | — | — | CN | claimed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | claimed |
| CN-110003219-A | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-105367577-B | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| EP-0362729-A1 | Process for producing water insoluble azo dyes on the fibre | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | KDM1A 328/4885ALDH1A1 2519/4885GAA 4543/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | KDM1A 328/4885ALDH1A1 2519/4885GAA 4543/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | KDM1A 328/4885ALDH1A1 2519/4885GAA 4543/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | KDM1A 328/4885ALDH1A1 2519/4885GAA 4543/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | KDM1A 328/4885ALDH1A1 2519/4885GAA 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.